This two center, cohort trial is designed to evaluate the safety and potential in vivo antiviral effects of a human anti-CMV monoclonal antibody SDZ MSL 109) compared to Sandoglobulin when administered intravenously every two weeks for six months to AIDS patients with CMV viruriaviremia but no clinical CMV disease.
Showing the most recent 10 out of 570 publications